hotspot -WSS

hotspot

author：comprehensive 2025-10-02 12:01:53 - browse：57

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： How to keep neuroscience’s past racism from being its future

WSS

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

What STAT readers think about the FDA and patient advocacy

Mark Cuban is blaming the wrong people for high drug costs

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Judge sides with young activists in first

Readout Newsletter: The latest on Moderna, Apellis, and Merck

entertainment

hotspot

leisure time

Apple is now the first public company to be valued at $3 trillion

Three trends to watch in biotech in 2024

Medical leaders decry Supreme Court decision on affirmative action

What to know about the judge who will handle the Trump case

ChatGPT in medicine: STAT answers readers' burning questions

What to know about the judge who will handle the Trump case

Peter Hotez and the public health issue of online harassment

Surge in Apellis stock fueled by confidence in safety of its eye drug

How to save PrEP access — and even expand it

Idaho college killings prosecutors challenge defense's grand jury claims

focus

Three trends to watch in biotech in 2024

Biogen’s boardroom scandal saddles CEO with first crisis

Aspartame and sugar

Montana youths win climate lawsuit against state for promoting fossil fuels

Bird flu researchers hone in on Finland’s mink farms

Maui wildfire now ranks as the fifth

focus

Wikipedia

explore

knowledge